Antibody-Based Strategies to Prevent and Treat Influenza
Open Access
- 13 July 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 315
- https://doi.org/10.3389/fimmu.2015.00315
Abstract
Passive immunization using antibodies has been suggested to offer several benefits in comparison to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents. However, until recently, antibody-based strategies to combat infectious agents has been hampered due to the fact that typical antibodies have been found to be strain-specific, with the virus evolving resistance in many cases. The discovery of broadly neutralizing antibodies (bNAbs) in, for example, influenza, dengue virus, and HIV, which bind to multiple, structurally-diverse strains has provided renewed interest in this area. This review will focus on new technologies that enable the discovery of bNAbs, the challenges and opportunities of immunotherapies as an important addition to existing antiviral therapy, and the role of antibody discovery in informing rational vaccine discovery – with agents targeting influenza specifically addressed. Multiple agents have entered the clinic and raise the possibility that a single antibody or small combination of antibodies can effectively neutralize a wide variety of strains. However, challenges remain - including combating escape variants, pharmacodynamics of antibody distribution, and development of efficacy biomarkers beyond virologic endpoints.This publication has 42 references indexed in Scilit:
- Influenza viral neuraminidase primes bacterial coinfection through TGF-β–mediated expression of host cell receptorsProceedings of the National Academy of Sciences of the United States of America, 2014
- Networks link antigenic and receptor-binding sites of influenza hemagglutinin: Mechanistic insight into fitter strain propagationScientific Reports, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A HemagglutininsScience, 2011
- Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2010
- Monoclonal antibody-based therapies for microbial diseasesVaccine, 2009
- Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B CellsPLOS ONE, 2008
- Co-morbidities associated with influenza-attributed mortality, 1994–2000, CanadaVaccine, 2008
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000